Equity Profile

BCRX

BioCryst Pharmaceuticals, Inc.

Health CareBiotechnology$2.5B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative medicines for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will reflect how well the company is managing its costs and generating revenue.

$0.23

Revenue

Total revenue gives insight into the company's sales performance, particularly as it relates to its product pipeline and market demand.

$183M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative medicines for rare diseases. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the demand for specialized treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an EPS of -$2.98, significantly missing expectations. This disappointing performance led to a 2.21% decline in stock price the following day.

Management Promises & Guidance

Management committed to improving operational efficiency.
They emphasized ongoing clinical trials for key products.
Plans to enhance market penetration for existing treatments were discussed.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic, expecting BioCryst to report a recovery in EPS and revenue after a disappointing last quarter. The consensus estimates suggest a rebound in performance.

Bull Case

If BioCryst meets or exceeds the EPS and revenue estimates, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its product pipeline and management effectiveness, leading to further stock declines.

Key Metrics to Watch

EPS

$0.23

Earnings per share is a key indicator of profitability and will reflect how well the company is managing its costs and generating revenue.

Revenue

$183M

Total revenue gives insight into the company's sales performance, particularly as it relates to its product pipeline and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioCryst achieve an EPS of at least $0.23 this quarter?

This EPS figure is critical for demonstrating a turnaround after last quarter's significant loss.

What revenue figures will BioCryst report, and how do they align with the $183 million consensus?

Revenue performance is essential for assessing the company's market traction and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for BioCryst to recover quickly, given its recent product advancements and market strategies.

Supporting Evidence

The company has a history of surprising analysts positively, with a 63% EPS beat rate.

Options pricing suggests a significant move, indicating that traders expect volatility which may not align with the consensus outlook.

Key Risk

If the company reports revenue significantly above $235 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are pivotal for assessing BioCryst's recovery trajectory and market confidence.

Bull Confirmed If

Achieving an EPS of $0.23 or better would confirm the bull case and suggest effective management and product performance.

Bear Confirmed If

An EPS below $0.08 would indicate ongoing struggles and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests a potential average stock move of +7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could see cautious commentary drive slight fluctuations.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of -8.34% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial progress for key products.
2Any changes in management's outlook on market conditions.
3Details on cost management strategies and operational efficiency.
4Insights into sales performance for existing treatments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative medicines for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will reflect how well the company is managing its costs and generating revenue.

$0.23

Revenue

Total revenue gives insight into the company's sales performance, particularly as it relates to its product pipeline and market demand.

$183M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an EPS of -$2.98, significantly missing expectations. This disappointing performance led to a 2.21% decline in stock price the following day.

Management Promises & Guidance

Management committed to improving operational efficiency.
They emphasized ongoing clinical trials for key products.
Plans to enhance market penetration for existing treatments were discussed.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic, expecting BioCryst to report a recovery in EPS and revenue after a disappointing last quarter. The consensus estimates suggest a rebound in performance.

Bull Case

If BioCryst meets or exceeds the EPS and revenue estimates, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations again, it may raise concerns about its product pipeline and management effectiveness, leading to further stock declines.

Key Metrics to Watch

EPS

$0.23

Earnings per share is a key indicator of profitability and will reflect how well the company is managing its costs and generating revenue.

Revenue

$183M

Total revenue gives insight into the company's sales performance, particularly as it relates to its product pipeline and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioCryst achieve an EPS of at least $0.23 this quarter?

This EPS figure is critical for demonstrating a turnaround after last quarter's significant loss.

What revenue figures will BioCryst report, and how do they align with the $183 million consensus?

Revenue performance is essential for assessing the company's market traction and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for BioCryst to recover quickly, given its recent product advancements and market strategies.

Supporting Evidence

The company has a history of surprising analysts positively, with a 63% EPS beat rate.

Options pricing suggests a significant move, indicating that traders expect volatility which may not align with the consensus outlook.

Key Risk

If the company reports revenue significantly above $235 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are pivotal for assessing BioCryst's recovery trajectory and market confidence.

Bull Confirmed If

Achieving an EPS of $0.23 or better would confirm the bull case and suggest effective management and product performance.

Bear Confirmed If

An EPS below $0.08 would indicate ongoing struggles and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests a potential average stock move of +7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could see cautious commentary drive slight fluctuations.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of -8.34% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial progress for key products.
2Any changes in management's outlook on market conditions.
3Details on cost management strategies and operational efficiency.
4Insights into sales performance for existing treatments.